Investor facts

Optos plc is a leading retinal imaging company with a vision to be recognized as the leading provider of retinal diagnostics through leveraging its unique ultra-widefield imaging technology.

Over 30 million optomap exams have been performed worldwide, helping us to secure our leading position in retinal diagnostics

Investor Factsheet
Investor Factsheet

 

 

Download December 2011 pdf version

Download August 2011 pdf version

Download December 2010 pdf version

Download August 2010 pdf version Download PDF

Download June 2010 pdf version Download PDF

Download March 2010 pdf version Download PDF

Download An Introduction to Optos - Building The Retina Company  Download PDF

Quick facts


  • Founded in 1992, IPO on LSE Main Market 2006.  Operations in North America and Europe
  • Over 32m optomap exams performed to date
  • Initially, devices used primarily in “wellness screening” to verify eye health.  Newer devices with increased functionality used in treatment regimes
  • 82% of Optos’ business is in the North America. We are growing quickly in Europe and expanding into new markets through new distribution  channels and directly in Australia
  • 95% of Optos’ revenue is from the core optometry sector with growing presence in ophthalmology
  • Optos has < 20% market penetration in ‘target sectors’ in existing markets - providing significant  growth potential